Do Libido Supplements Actually Work for Women?

An Evidence-Graded Review of Over-the-Counter Botanicals and the Two FDA-Approved Prescription Options

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and it is not a substitute for individualized care. Supplements and prescription medications carry real risks and interactions. Do not start, stop, or change any therapy without consulting a qualified healthcare provider who knows your full history.

The honest headline first: for the great majority of over-the-counter libido products marketed to women, the evidence that they outperform a placebo is thin, inconsistent, or absent. Most have never been tested in a rigorous randomized trial, and where trials exist they are usually small, short, and industry-funded. A handful of ingredients do show a real—though modest—signal. And the two prescription medications approved for low desire have the strongest data of anything in this space, yet still deliver effect sizes most clinicians would call small.

None of that means "nothing works." It means the useful question is rarely which bottle—it is why has desire changed, and what is actually driving it. This review walks through that reasoning first, then grades the ingredients one by one against what the published literature does and does not support.

Start With the Differential, Not the Supplement Aisle

Low sexual desire is a symptom, not a diagnosis. Before any botanical is worth considering, the more productive step is to look for a treatable driver. In clinical practice these cluster into five buckets:

• Hormonal shifts — perimenopause and menopause, low testosterone, the postpartum period, thyroid dysfunction, PCOS, and hormonal contraception (which lowers free testosterone in some women).

• Medications — SSRIs and SNRIs are the classic culprits; some antihypertensives, antipsychotics, and hormonal agents also blunt desire.

• Medical conditions — diabetes, cardiovascular disease, chronic pain and fatigue, and genitourinary changes such as vaginal dryness or atrophy that make sex uncomfortable.

• Psychological factors — depression, anxiety, chronic stress, body-image concerns, and a history of trauma.

• Relationship and lifestyle factors — sleep debt and fatigue, alcohol, relationship conflict, and simple lack of unpressured time and communication.

When one of these is the real driver, the supplement question becomes secondary—treating the cause (adjusting a medication, addressing atrophy, treating depression, protecting sleep) tends to do far more than any capsule. Hypoactive sexual desire disorder (HSDD), the formal diagnosis, requires that low desire be persistent and personally distressing, and that other explanations have been reasonably excluded.

How to Read the Evidence: Effect Size and the Placebo Problem

Two ideas make the rest of this article interpretable. First, effect size (Cohen's d) describes how large a treatment's benefit is beyond placebo: roughly 0.2 is small, 0.5 medium, and 0.8 large. Second, the placebo response in sexual-function trials is unusually high—women in placebo arms routinely report meaningful improvement, because expectation, attention, and simply focusing on intimacy all have genuine effects. Any product's real-world value is only the slice above that placebo response, which is why so many "it worked for me" reports do not survive a controlled trial.

Most female sexual-function trials measure outcomes with the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS). Keep those two anchors—effect size and the placebo curve—in mind as we go.

The Prescription Options: Best Data, Still Modest

Flibanserin (Addyi)

A daily oral medication acting on serotonin and dopamine pathways in the brain, approved for acquired, generalized HSDD in premenopausal women. Across the pivotal trials, the effect versus placebo landed in the small range—improvements in desire and reductions in distress with effect sizes around 0.3 to 0.4—and a 2016 systematic review and meta-analysis concluded the benefit amounted to roughly half of one additional satisfying sexual event per month over placebo. The FDA's own review described the average treatment effect as small while noting some women found it clinically meaningful. The safety caveats are not trivial: flibanserin can cause central-nervous-system depression, and this risk rises sharply with alcohol and with drugs that raise its blood levels.

Bremelanotide (Vyleesi)

An on-demand injectable melanocortin-receptor agonist, self-administered before anticipated activity, also approved for premenopausal HSDD. In the RECONNECT phase 3 trials, it significantly improved desire and reduced distress versus placebo, again with small effect sizes (roughly 0.3 relative to placebo). Nausea is common, and transient blood-pressure elevation means it is avoided in women with uncontrolled hypertension or established cardiovascular disease.

The takeaway is not that these drugs fail—they have the most rigorous evidence base in the field—but that even the best-studied options move the needle modestly. That reframes expectations for anything sold without a prescription.

The Botanicals and Nutraceuticals, Graded

The table below sorts the common ingredients by the strength and consistency of their human trial evidence for female desire or sexual function, not by popularity or marketing. "Reasonable signal" still means small, short trials—it is a relative grade within a low-evidence field.

Tier	Ingredient & what the trials show	Best-fit context
Most consistent signal	Saffron, ashwagandha, and a tribulus RCT each showed FSFI improvement vs placebo in randomized trials. Maca helped orgasm/arousal chiefly in peri- and postmenopausal women and in SSRI-induced dysfunction.	Menopausal transition; SSRI-associated low desire
Modest / context-dependent	L-arginine combination products (e.g., ArginMax) improved self-reported desire across menopausal status. Fenugreek extract (Libifem) showed benefit in one RCT. Chasteberry has a small signal in postmenopausal women.	Women wanting a lower-risk first step
Mixed / inconclusive	Ginseng, ginkgo. Red clover has solid evidence for hot flushes but only indirect, weak data for desire itself. Effects are inconsistent across studies.	Not reliable as a primary strategy
Evidence points the other way	Oral DHEA: the best randomized trial in postmenopausal women with low libido found no significant benefit over placebo at 50 mg/day, with androgenic side effects (acne, hair growth). Often listed as "supported"—the controlled data don't back that for oral DHEA and low desire.	Not supported for this use

A closer look at the standouts

• Saffron (Crocus sativus). Randomized, placebo-controlled trials—including in women with fluoxetine-induced sexual dysfunction—have shown improvement in FSFI scores, and a meta-analysis supports a benefit across sexual-function domains. Among botanicals, this is some of the more reproducible signal.

• Ashwagandha (Withania somnifera). A placebo-controlled RCT in women with low FSFI scores found significant gains in total FSFI, arousal, lubrication, orgasm, and satisfaction. Plausibly works partly through stress and cortisol pathways rather than hormones directly.

• Maca (Lepidium meyenii). A systematic review called the overall evidence limited, but the signal is strongest in specific groups: menopausal women, and women with SSRI-induced dysfunction, where a small trial showed benefit concentrated in postmenopausal participants. Notably, it does not appear to raise testosterone.

• Tribulus terrestris. A randomized, double-blind trial in women with HSDD reported significant FSFI improvement over four weeks. Encouraging but short, and single-trial evidence should be held loosely.

• L-arginine combinations. Products combining L-arginine with ginseng, ginkgo, and other botanicals (ArginMax) improved self-reported desire and satisfaction across menopausal status in company-associated trials; a later systematic review found L-arginine-based formulas the best-studied of this category, though blinding and funding limit confidence.

• DHEA—the honest correction. Oral DHEA is frequently listed among "ingredients with support," but the strongest randomized trial in postmenopausal women with low libido found no significant improvement over placebo, while causing androgenic side effects. (A separate, FDA-approved intravaginal form, prasterone, is used for painful sex from vaginal atrophy—a different problem than low desire.)

Who Might Reasonably Try Them—And Who Should Not

May be reasonable candidates

• Peri- and postmenopausal women whose desire change tracks with hormonal transition, once atrophy and other drivers are addressed.

• Women with no identifiable treatable cause who want a lower-risk first step before, or alongside, discussing prescription options with a clinician.

• Women with SSRI-associated low desire, where saffron and maca have the most relevant trial data—though adjusting the antidepressant with the prescriber is often the higher-yield move.

Should generally avoid, or proceed only with medical oversight

• Anyone pregnant or breastfeeding.

• Women on blood thinners, or with uncontrolled cardiovascular disease.

• Women with hormone-sensitive cancers (breast, uterine), given phytoestrogenic ingredients such as red clover.

• Women with bipolar disorder or a seizure disorder, and those taking MAOIs.

• Women taking SSRIs, insulin, or other medications with meaningful interaction potential—coordinate first.

• Anyone approaching surgery (bleeding and anesthesia interactions).

• Anyone already taking flibanserin, which interacts dangerously with alcohol and can be affected by botanicals such as ginkgo and St. John's wort.

The Clinical Bottom Line

Libido supplements are best understood as a low-probability, generally-low-risk experiment—reasonable to try in the right person, but not a substitute for finding the actual driver of low desire. If a specific cause exists, treating it is almost always more effective than any capsule. If a woman wants to try a supplement, saffron and ashwagandha have the most defensible evidence, maca is worth considering in the menopausal or SSRI context, and oral DHEA is the one commonly-promoted ingredient the controlled data do not support for this purpose. And because "natural" is not the same as "inert," the safety and interaction screen above matters as much as the efficacy question.

If you would like a personalized, evidence-based evaluation of low desire—including the hormonal, medication, and lifestyle contributors that supplements can't fix—my integrative practice is at www.directintegrativecare.com.

Selected References

1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899–908.

2. Jaspers L, Feys F, Bramer WM, et al. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis. JAMA Intern Med. 2016;176(4):453–462.

3. U.S. FDA, Center for Drug Evaluation and Research. Flibanserin (Addyi) Summary Review, NDA 022526. 2015.

4. Kashani L, Raisi F, Saroukhani S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol. 2013;28(1):54–60.

5. Ajgaonkar A, Jain M, Debnath K. Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract for Improvement of Sexual Health in Healthy Women: A Prospective, Randomized, Placebo-Controlled Study. Cureus. 2022;14(10):e30787.

6. Dording CM, Schettler PJ, Dalton ED, et al. A Double-Blind Placebo-Controlled Trial of Maca Root as Treatment for Antidepressant-Induced Sexual Dysfunction in Women. Evid Based Complement Alternat Med. 2015;2015:949036.

7. Shin BC, Lee MS, Yang EJ, Lim HS, Ernst E. Maca (L. meyenii) for improving sexual function: a systematic review. BMC Complement Altern Med. 2010;10:44.

8. Akhtari E, Raisi F, Keshavarz M, et al. Tribulus terrestris for treatment of sexual dysfunction in women: randomized double-blind placebo-controlled study. Daru. 2014;22(1):40.

9. Ito TY, Trant AS, Polan ML. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J Sex Marital Ther. 2001;27(5):541–549.

10. Ito TY, Polan ML, Whipple B, Trant AS. The enhancement of female sexual function with ArginMax among women differing in menopausal status. J Sex Marital Ther. 2006;32(5):369–378.

11. Systematic Review of l-Arginine for the Treatment of Hypoactive Sexual Desire Disorder and Related Conditions in Women. Pharmacy (Basel). 2021;9(2):71.

12. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med. 2009;6(9):2579–2590.

13. Kanadys W, Barańska A, Błaszczuk A, et al. Evaluation of Clinical Meaningfulness of Red Clover Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis. Nutrients. 2021;13(4):1258.

https://youtu.be/qNxc1mc9yA8?si=5Pj2sA7FPH-PB1eY

About Dr. Kim

Dr. Yoon Hang "John" Kim is a board-certified physician with more than 20 years of experience in integrative and functional medicine. He completed a fellowship under Dr. Andrew Weil at the University of Arizona and holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 3 books and more than 20 peer-reviewed articles.

Professional: www.yoonhangkim.com   |   Clinical: www.directintegrativecare.com